Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 13/20 | 0.44 |
| ▸ | ADRB2 | P07550 | 12/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | SLC5A7 | Q9GZV3 | 1/20 | 0.38 |
| ▸ | HTR7 | P34969 | 2/20 | 0.36 |
| ▸ | HTR1A | P08908 | 1/20 | 0.36 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4493960 | 0.94 | CHRM2 (0.42) | CHRM3ADRB2CHRM2SLC5A7HTR7 | |
| SCHEMBL4480089 | 0.94 | CHRM2 (0.43) | CHRM3ADRB2CHRM2SLC5A7HTR7 | |
| SCHEMBL4494191 | 0.94 | CHRM2 (0.43) | CHRM3ADRB2CHRM2SLC5A7HTR1A | |
| SCHEMBL4493963 | 0.94 | CHRM3 (0.45) | CHRM3ADRB2CHRM2SLC5A7 | |
| SCHEMBL4494455 | 0.91 | CHRM2 (0.43) | CHRM3ADRB2CHRM2DRD2 | |
| SCHEMBL4484438 | 0.91 | CHRM3 (0.43) | CHRM3ADRB2CHRM2DRD2 | |
| SCHEMBL4491995 | 0.91 | CHRM2 (0.41) | CHRM3ADRB2CHRM2SLC5A7HTR7 | |
| SCHEMBL4490830 | 0.91 | CHRM2 (0.44) | CHRM3ADRB2CHRM2SLC5A7HTR7 | |
| SCHEMBL4475841 | 0.90 | CHRM2 (0.43) | CHRM3ADRB2CHRM2SLC5A7HTR7 | |
| SCHEMBL4483245 | 0.90 | CHRM3 (0.42) | CHRM3ADRB2CHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632847-B2 | Bronchodilators; treating chronic obstructive pulmonary disease or asthma; long duration of action; reduced side effects, such as dry-mouth and constipation; e.g. biphenyl-2-ylcarbamic acid 1-(2-(3-[3-(4-hydroxybenzylamino)propionylamino]benzoylamino)ethyl)piperidin-4-yl ester | THERAVANCE, INC. (US) | 2009-12-15 | — | — | US | disclosed |